当前位置: 首页 > 详情页

Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease

| 导出 | |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [a]Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Beijing, China [b]Key Neurodegenerative Laboratory of Ministry of Education, Beijing, China [c]Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
出处:
ISSN:

关键词: Alzheimer's disease biomarkers dynamin-related protein 1 Fis1 peripheral blood lymphocytes

摘要:
Background and purpose: Expression of the mitochondrial fission proteins dynamin-related protein 1 (Drp1), S-nitrosylated Drp1 (SNO-Drp1), and Fis1 has been found to be altered in brain tissues and skin fibroblasts from patients with Alzheimers disease (AD). The aim of this study was to determine whether these proteins are also changed in peripheral blood lymphocytes (PBL) of AD patients and whether these changes are specific and sensitive enough for AD diagnosis. Methods: Western blot analysis and enzyme-linked immunosorbent assay (ELISA) were employed to quantify relative levels of Drp1, SNO-Drp1, and Fis1 in PBL obtained from 91 controls, 82 AD, 26 mild cognitive impairment (MCI), 12 Parkinsons disease (PD), and 36 vascular dementia (VaD) patients. Logistic regression and receiver operating characteristic (ROC) curve analysis were used to measure diagnostic accuracy of these proteins. Results: Compared with controls, SNO-Drp1 and Fis1 levels were remarkably increased in PBL of AD and MCI patients, and Drp1 was significantly decreased in AD, MCI, and PD. None of these proteins were changed in VaD patients. Disease severity or duration had no major effects on levels of these proteins in AD PBL. ROC curve analysis showed that the specificity and sensitivity were 81% and 73% for Drp1, 84% and 82% for SNO-Drp1, and 89% and 80% for Fis1 in identifying AD patients from control subjects. Conclusions: Altered mitochondrial fission proteins Drp1, SNO-Drp1, and Fis1 in PBL were relatively sensitive and specific in identifying AD patients and could be serving as a biomarker in the procedure of diagnosis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 神经科学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 神经科学 3 区 临床神经病学
JCR分区:
出版当年[2010]版:
Q1 CLINICAL NEUROLOGY Q2 NEUROSCIENCES
最新[2023]版:
Q1 CLINICAL NEUROLOGY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者机构: [a]Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Beijing, China [b]Key Neurodegenerative Laboratory of Ministry of Education, Beijing, China
通讯作者:
通讯机构: [*1]Department of Neurology, Xuan Wu Hospital of the Capital Medical University, 45 Changchun Street, Beijing 100053, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院